Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Updates on metastatic bladder cancer from ASCO GU 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.02.19
Views: 2095

Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA

Prof Arlene Siefker-Radtke talks about the data presented at ASCO GU 2019 and the potential impact on treatment landscape in metastatic urothelial cancer.

She highlights the abstract sessions, including exciting new information on sacituzumab and pegylated interleukin-2, as well as the potential of free circulating tumour DNA analyses.

Finally, she discusses the implications of the studies presented at ASCO GU and looks to the future for both patient outcomes and current treatment schedules.

Clinical evidence for the activity of vofatmab in patients with urothelial cancer
Therapeutic profile of gemcitabine-carboplatin vs. gemcitabine-oxaliplatin
Sacituzumab as a targeted therapy for metastatic urothelial carcinoma
Clinical activity of bempegaldesleukin
The detection of circulating free DNA in FGFR-mutant tumours
Future therapies for bladder cancer patients

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation